1. Home
  2. RLJ vs ERAS Comparison

RLJ vs ERAS Comparison

Compare RLJ & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RLJ Lodging Trust of Beneficial Interest $0.01 par value

RLJ

RLJ Lodging Trust of Beneficial Interest $0.01 par value

HOLD

Current Price

$8.39

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$11.58

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLJ
ERAS
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
RLJ
ERAS
Price
$8.39
$11.58
Analyst Decision
Hold
Strong Buy
Analyst Count
7
9
Target Price
$8.75
$5.78
AVG Volume (30 Days)
1.6M
7.1M
Earning Date
02-26-2026
03-19-2026
Dividend Yield
7.23%
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$1,351,163,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.36
N/A
P/E Ratio
$188.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.16
$1.01
52 Week High
$9.85
$12.48

Technical Indicators

Market Signals
Indicator
RLJ
ERAS
Relative Strength Index (RSI) 68.99 73.97
Support Level $7.26 $9.05
Resistance Level $7.92 $12.48
Average True Range (ATR) 0.22 0.72
MACD 0.09 -0.06
Stochastic Oscillator 98.70 73.91

Price Performance

Historical Comparison
RLJ
ERAS

About RLJ RLJ Lodging Trust of Beneficial Interest $0.01 par value

RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: